Comparison of CD146 Positive and Negative Mesenchymal Stem Cells in Improving Premature Ovarian Failure

The study compared the therapeutic efficacy of CD146 + and CD146 - mesenchymal stem cells (MSCs) in treating premature ovarian failure (POF) using a mouse model. Both MSC types improved ovarian function, increased ovarian follicles, and restored hormone levels, but CD146 + MSCs demonstrated superior proliferation, immune modulation, and cytokine secretion. CD146 + MSCs were more effective in reversing lymphocyte changes and persisted longer in vivo, suggesting better immune regulation. The study concluded that while both MSC subpopulations were beneficial, CD146 + MSCs offered a slight advantage in efficacy, highlighting their potential for regenerative therapies in POF.